KRAS mutations correlates with P53 status in colorectal carcinomas

Natalia Rodón1, Ruth Román1, Montse Verdú1,3, Miquel Calvo4, Beatriz García-Peláez1, Marta González1, Carme Pubill3 y Xavier Puig1,2,3.

1BIOPAT. Biopatologia Molecular, SL, Grup Assistència; 2Hospital de Barcelona-SCIAS, Grup Assistència; 3Histopat Laboratoris; 4Departament d’Estadística, Universitat de Barcelona. Barcelona

Background:

KRAS mutations, present in approximately 30-50% of colorectal carcinomas (CRC) has been recently associated with lack of response to anti-EGFR therapy, poor prognosis and high mitotic activity. Nevertheless, its relation to other histopathological and molecular parameters has not been well established.

Our first approach was to determine […]

2009-09-23T17:20:26+00:00

Fórmula de predicción de inestabilidad de microsatélites en el cáncer colorectal en base a parámetros morfológicos. Estudio multicéntrico prospectivo de validación y optimización del modelo

R Román1, M Verdú1,3, A Vidal3,5, M Calvo4, X Sanjuan5, M Jimeno6, A Salas7, J Autonell8, I Trias9, M González1, B García1, N Rodón1 y X Puig1,2,3.

1BIOPAT. Biopatologia Molecular, SL, Grup Assistència; 2Hospital de Barcelona-SCIAS, Grup Assistència; 3Histopat Laboratoris; 4Departament d’Estadística, Universitat de Barcelona; 5Hospital Universitari de Bellvitge; 6Hospital del Mar; 7Hospital Mútua de Terrassa; 8Hospital General de Vic; 9Hospital Plató, Barcelona.

Introducción: La inestabilidad de microsatélites (MSI-H) identifica un grupo de carcinomas colorectales de mejor pronóstico y con riesgo […]

2009-05-23T17:19:19+00:00

Multicentric validation of a model based on phenotypic features to predict microsatellite instability in colorectal adenocarcinoma

R ROMAN1, M VERDU1,3, A VIDAL3,5, M CALVO4, X SANJUAN5, M JIMENO6, A SALAS7, J AUTONELL8, I TRIAS9, N RODON1, M GONZALEZ1, B GARCIA1 and X PUIG1,2,3.

1BIOPAT.Biopatologia Molecular, Barcelona, Spain; 2Hospital de Barcelona, Barcelona, Spain; 3Histopat Laboratoris, Barcelona, Spain; 4Statistics Department, Universitat de Barcelona, Barcelona, Spain; 5Hospital Universitari de Bellvitge, Barcelona, Spain; 6Hospital del Mar, Barcelona, Spain; 7Hospital Mútua de Terrassa, Terrasa, Spain; 8Hospital General de Vic, Vic, Spain and 9Hospital Plató, Barcelona, Spain.

Background: High microsatellite instability (MSI-H) allows the […]

2009-03-23T17:17:26+00:00

Colo-rectal micropapillary carcinoma: a clinicopathological and molecular study of 27 cases

Ruth Roman1, Montse Verdú 1,3, August Vidal 1,3, Miquel Calvo 4, Natalia Rodón1, Beatriz García1, Marta González1 and Xavier Puig1,2,3.

1BIOPAT. Biopatologia Molecular, SL, Grup Assistencia; 2Hospital de Barcelona SCIAS, Grup Assistència; 3Histopat Laboratoris and 4Statistics Department, Universitat de Barcelona. Barcelona, Spain.

INTRODUCTION: Invasive micropapillary carcinoma (MC) is associated with frequent lymph node metastasis and adverse clinical outcome. It has been reported in ovary, breast, urinary bladder, ureter, lung, parotid gland and, recently, in colon. Little is known about the morphological and […]

2008-05-23T17:13:35+00:00

A population study on the UGT1A1*28 variant associated to Irinotecan tolerance

Roman R,1 Colomer A,1 Erill N,1 Verdú M,2 Ibáñez R,1 Cordon-Cardo C,1 Puig X.1,2

1BIOPAT. Biopatologia Molecular, Grup Assistència & 2HISTOPAT Laboratoris, Barcelona, Catalonia, Spain.

Background: Irinotecan (CPT-11) is currently used as first- or second-line treatment for colorectal cancer, either alone or in combination with 5-fluorouracil based regimens. UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzes the inactivation of SN-38, the active metabolite of irinotecan, through glucuronidation. UGT1A1*28, a polymorphic variant of this enzyme displaying an additional TA dinucleotide in the promoter TATA box, has been […]

2006-09-23T17:11:42+00:00